Fractalkine (CX3CL1) levels in patients with Behcet's disease and Neuro-Behcet's disease
Küçük Resim Yok
Tarih
2012
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
ELSEVIER SCIENCE BV
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Objective: The aim of the present study was to assess the role of CX3CL1 in patients with active and inactive Behcet's Disease (BD), Neuro-Behcet's Disease (NBD) and control subjects. Methods: Fifty-six patients admitted to the BD and NBD Outpatient Clinics, and 30 healthy controls were enrolled in the study. Serum CX3CL1 levels were measured by an enzyme linked immunosorbent assay (ELISA). Results: No significant difference was found between the serum CX3CL1 levels of control subjects, and patients with active and inactive BD or NBD, regardless of treatment. Conclusion: To our knowledge, this is the first study analyzing CX3CL1 levels in patients with BD and NBD. Our results demonstrated that serum CX3CL1 levels were not changed in active and inactive BD and NBD. However, further large-scale studies are needed to confirm our results. (C) 2011 Elsevier B.V. All rights reserved.
Açıklama
Anahtar Kelimeler
Behcet's disease, Neuro-Behcet's disease, Fractalkine (CX3CL1)
Kaynak
JOURNAL OF THE NEUROLOGICAL SCIENCES
WoS Q Değeri
Q2
Scopus Q Değeri
Q2
Cilt
315
Sayı
01.02.2020
